Summary All-trans-retinoic acid (ATRA) is well known to inhibit the proliferation of human breast cancer cells. Much less is known about the antiproliferative activity of the naturally occurring metabolites and isomers of ATRA. In the present study, we investigated the antiproliferative activity of ATRA, its physiological catabolites 4-oxo-ATRA and 5,6-epoxy-ATRA and isomers 9-cis-RA and 1 3-cis-RA in MCF-7 human breast cancer cells by bromodeoxyuridine incorporation. MCF-7 cells were grown in steroid-and retinoid-free medium supplemented with growth factors. Under these culture conditions, ATRA and its naturally occurring catabolites and isomers showed significant antiproliferative activity in MCF-7 cells in a concentration-dependent manner (10-11 M to 10-M). The antiproliferative activity of ATRA catabolites and isomers was equal to that of the parent compound ATRA at concentrations of 10-M and 1 07 M. Only at 10-6 M were the catabolites and the stereoisomer 1 3-cis-RA less potent. The stereoisomer 9-cis-RA was as potent as ATRA at all concentrations tested (1 0-11 M to 10-M). In addition, we show that the catabolites and isomers were formed from ATRA to only a limited extent. Together, our findings suggest that in spite of their high antiproliferative activity the catabolites and isomers of ATRA cannot be responsible for the observed growth inhibition induced by ATRA.
family and function as ligand-dependent transcription factors (Chambon, 1996) . The RAR family is activated both by ATRA and by 9-cis-RA, whereas the RXR family is activated exclusively by 9-cis-RA (Chambon, 1996) . The ability of the natural stereoisomer 13-cis-RA to bind to RARs is controversial.
Diversity in the control of gene expression by RA exists because of the complexity at different levels of the signalling pathway. An important level in this complex retinoid signalling pathway is represented by the existence of natural metabolites of all-trans-RA (ATRA), whose synthesis may be modulated cell specifically (Napoli, 1996) . ATRA metabolism has been studied in a variety of tissues and a number of metabolites have been identified ( Figure 1 ). One important catabolic pathway for ATRA is initiated by hydroxylation at the four position of the P-ionone ring of ATRA to yield 4-hydroxy-ATRA (Frolik et al, 1979; Roberts et al, 1980 ). This step is catalysed by a cytochrome P450-dependent ATRA 4-hydroxylase (Roberts et al, 1980; White et al, 1996) . 4-Hydroxy-ATRA is further oxidized via 4-oxo-ATRA to more polar metabolites (Roberts et al, 1980) . This latter step involves at least one other, presently unknown, cytochrome P450-dependent ously non-enzymatic process (Urbach and Rando, 1994) .
Cancer cells have been shown to possess RA catabolic activity. Oxidative catabolism of RA to more polar metabolites was observed in N-methyl-N-nitrosourea-induced mammary tumours in the rat (Bhat and Lacroix, 1989) , in rat Dunning R3327G prostate tumours (Krekels et al, 1996) , F9 mouse teratocarcinoma cells (Williams and Napoli, 1985) , LLC-PK1 pig kidney cancer cells (Napoli, 1986) , BA-HAN-IC rat rhabdomyosarcoma cells (Biesalski et al, 1990) , as well as in the human breast cancer cells MCF-7 (Wouters et al, 1992; Krekels et al, 1997) and T47D (Han and Choi, 1996) .
Recently, Takatsuka et al (1996) showed a positive relationship between metabolism of ATRA in human breast cancer cells and the antiproliferative activity of ATRA, suggesting that an undefined metabolite of ATRA, rather than the parent compound itself, could be responsible for the observed growth inhibition induced by ATRA. To date, only limited and conflicting results have been published concerning the activity of the naturally occurring ATRA metabolites in tumours. To clarify these points, we studied the antiproliferative activity of ATRA, its physiological catabolites 4-oxo-ATRA and 5,6-epoxy-ATRA and isomers 9-cis-RA and 13-cis-RA in MCF-7 cells using a bromodeoxyuridine incorporation assay. Bromodeoxyuridine labelling is considered an accurate method to measure cell proliferation because it is a direct assay of DNA synthesis (Dolbeare, 1995) . Furthermore, the antiproliferative activities could only be properly studied in a steroid-and retinoid-free medium, because of the presence of endogenous retinoids in serum. Therefore, MCF-7 cells were grown in a phenol red-free medium supplemented with charcoal-treated fetal bovine serum and growth factors. ATRA was obtained from Serva (Heidelberg, Germany) and 13-cis-RA was purchased from Eastman Kodak (Rochester, NY, USA). 9-cis-RA, 4-oxo-ATRA and 5,6-epoxy-ATRA were a generous gift from Dr M Klaus (Hoffmann La Roche, Basle, Switzerland). All retinoids were dissolved in ethanol to an initial concentration of 4 mm and appropriately diluted in culture medium. The final solvent concentration during the proliferation studies was always < 0.5% (v/v). The retinoid stock solutions were checked for purity using HPLC analysis. Experiments with retinoids were always performed in a dark room with yellow illumination.
Preparation of dextran-coated charcoal (DCC)-treated fetal bovine serum (FBS) DCC-treated FBS was prepared as described by Horwitz and McGuire (1978 glutamine, 1 mm sodium pyruvate and 50,g ml-' gentamicin (all reagents from Life Technologies). The MCF-7 subclone used in this study has been characterized previously (Van heusden et al, 1996) . Cells were grown in a humidified incubator (5% carbon dioxide, 95% air) at 37°C and were Mycoplasma-free as tested by the Mycoplasma TC kit (Gen-Probe Incorporated, CA, USA).
For the proliferation studies, the MCF-7 cells were cultured for 6 days in phenol red-free DMEM containing 5% (v/v) DCCtreated FBS, 4.5 g -1 of glucose, 2 mM L-glutamine, 1 mM sodium British Journal of Cancer (1998) and its isomers 9-cis-RA (D) and 1 3-cis-RA (E) in MCF-7 cells. Cells were cultured for 7 days in the presence of test compounds. Cell proliferation was measured by BrdU incorporation, as described in Materials and methods.
Results are presented as means ± s.d. of three (A, D, E) or five (B, C) experiments. *P < 0.01 and **P < 0.001 vs control cells (Mann-Whitney U-test). #P < 0.01 vs ATRA-treated cells (Mann-Whitney U-test) pyruvate, 50 jig ml-' of gentamicin, 30 nM sodium selenite and 10 jg ml-' of transferrin (all reagents from Life Technologies). Then, cells were seeded onto Chamber Slides (Nunc, Naperville, IL, USA) at a concentration of 15 000 cells per chamber. Chamber Slides has been coated with 50 jg ml-' of poly-L-lysine one day before use. Cells were allowed to attach for 24 h and thereafter the medium was supplemented with growth factors (10 jig ml' of final concentration insulin (Life Technologies) and 5 ng ml' of final concentration basic fibroblast growth factor (Life Technologies)) and retinoids (concentration ranging from 10-" M to 10 6 M). Cells were grown under these conditions for 7 days with medium changes 3 and 6 days after seeding.
Bromodeoxyuridine (BrdU) detection After 7 days of culture with retinoids as described above, MCF-7 cells were labelled with 100 gM BrdU for 2.5 h and fixed. 
HPLC analysis
Confluent MCF-7 cells, cultured in medium containing 5% DCCtreated FBS, were treated for 24 h with 106 M ATRA to induce ATRA catabolism (Wouters et al, 1992; Krekels et al, 1997) . Cells were then washed twice with 25 ml of culture medium, trypsinized and harvested. Cells were resuspended at a concentration of 4 x 106 cells ml-'. This cell suspension (450 jl) was incubated with 10-7M [11,12 -3H(N) ]ATRA for various times. After centrifugation for 10 min at 780 g, the supernatant was analysed for the presence of ATRA metabolites and isomers.
Analysis of ATRA metabolites Reverse-phase HPLC analysis was carried out on a Varian HPLC system consisting of a HPLC pump 9010, an autosampler 9095 and a diode array detector (Polyview, 9065). The STAR 4.0 data software (Varian, Harbor City, CA, USA) was used to analyse the chromatograms. Radioactivity in the eluate was monitored on-line by ,3-counting (Packard Radiomatic radioactivity monitor) using Ultima-flo M (Packard, Meriden, CT, USA) as the scintillation solvent. The samples (150 jil) were analysed on a Zorbax 5C8 column (4.6 mm i.d. x 250 mm, 5 jum; Chrompack). The mobile phase was methanol/2% acetic acid/acetonitrile (1.5:93:5.5) containing 40 mM ammonium acetate (solvent A). Solvent B consisted of methanol/2% acetic acid/acetonitrile (15:30:55) containing 40 mm ammonium acetate and solvent C was 100% methanol. A linear gradient at a flow rate of 1 ml min-' was performed for 25 min from 24% A-76% B to 15% A-85% B.
The solvent was then changed to 50% B-50% C in 15 min. To elute unchanged ATRA the solvent was changed to 100% C after 40 min.
Analysis of ATRA isomers
For the separation of the isomers of ATRA the same HPLC equipment was used. Samples (150 jl) were analysed on a Novapak column (3.9 mm i.d. ATRA and its naturally occurring catabolites and isomers significantly inhibit MCF-7 cell proliferation MCF-7 cells, grown in medium containing 5% DCC-treated FBS, showed a BrdU labelling index of 8.0 ± 1.0% (n = 3). Cells were stimulated to proliferate by the addition of 10 ,ug ml-' insulin and 5 ng ml-basic fibroblast growth factor, resulting in a BrdUlabelling index of 25.2 ± 1.4% (n = 5).
Under these culture conditions, ATRA inhibited the proliferation of MCF-7 cells in a concentration-dependent manner, at concentrations from 10-8 M to 10"M (Figure 2A ), which was reflected by a decrease in the BrdU-labelling index. At a concentration of 10 M, ATRA inhibited MCF-7 cell proliferation by 61 ±4% (n=3). Figure 2B shows that the ATRA catabolite 4-oxo-ATRA decreased the labelling index at concentrations ranging from 10-8 M to 10 M. At a concentration of 10-M, cell proliferation was inhibited by 37 ± 11% (n = 5).
5,6-epoxy-ATRA, another catabolite of ATRA, decreased the BrdU labelling index at 10-8 M to 106 M the same extent as 4-oxo-ATRA ( Figure 2C ).
The stereoisomer 9-cis-RA ( Figure 2D ) also inhibited MCF-7 cell proliferation in a concentration-dependent manner (10-8 M to 10" M). Note that 9-cis-RA was equipotent compared with ATRA at all concentrations tested. Figure 2E shows the antiproliferative activity of the stereo- Figure 3A , (Figure 4) . No peak co-eluting with authentic 5,6-epoxy-ATRA (retention time, 37 min) could be detected in the culture medium of cells that were pretreated to induce ATRA catabolism ( Figure 3A ). In the culture medium of cells that were not pretreated with ATRA or in the absence of cells, 5,6-epoxy-ATRA could not be detected at time points ranging from 30 min to 24 h (data not shown). Other polar metabolites were present in the cell culture medium ( Figure 3A ) but their nature remains to be identified. MCF-7 cells also converted ATRA into an apolar metabolite, that was not detected in the absence of cells. Figure 3B shows the isomers of ATRA that were formed when MCF-7 cells, pretreated for 24 h with 106 M ATRA, were incubated with 10-7 M [3H]ATRA. After 4 h, only about 30% of total radioactivity was recovered in the RA peak, i.e. ATRA and its stereoisomers 9-cis-RA and 13-cis-RA. This RA peak consisted of about 83% of ATRA, 8% of 13-cis-RA and 7% of 9-cis-RA. Similar isomer composition of the RA peak was obtained with cells that were not pretreated with ATRA and in the absence of cells (data not shown). After 24 h, only about 11% of total radioactivity was recovered in the RA peak of MCF-7 cells that were pretreated with ATRA (Figure 4 ). In the absence of cells about 80% of total radioactivity was recovered in the RA peak (data not shown). Under both culture conditions, the relative isomer composition was about 71% ATRA, 12% 13-cis-RA and 8% 9-cis-RA. An additional peak (peak i, Figure 3B ) could be detected but its nature remains unknown.
DISCUSSION
The present study demonstrates that not only ATRA itself, but also its naturally occurring catabolites 4-oxo-ATRA and 5,6-epoxy-ATRA as well as its isomers 9-cis-RA and 13-cis-RA possess significant antiproliferative activity in MCF-7 human breast cancer cells, grown in a steroid-and retinoid-free medium. A significant antiproliferative activity equal to that of ATRA, was observed with these metabolites at concentrations of 10-8 M and 10-7 M. At a concentration of 10 6 M, the ATRA catabolites and the stereoisomer 13-cis-RA were less potent than ATRA. The stereoisomer 9-cis-RA was as potent as ATRA at all concentrations tested (10-11 M to 106 M). As these catabolites and isomers were formed to only a limited extent, our findings suggest that they cannot be responsible for the observed growth inhibition induced by ATRA.
The antiproliferative activity of ATRA and its naturally occurring catabolites and isomers could only be properly studied in a steroid-and retinoid-free culture medium. For this purpose, phenol red-free medium (Berthois et al, 1986 ) was used supplemented with DCC-treated FBS (Horwitz and McGuire, 1978) . DCC-treatment of FBS is well known to remove endogenous steroids present in the serum (Horwitz and McGuire, 1978) . In this study, we showed that also ATRA was efficiently removed by DCC-treatment. This would result in a final concentration of 1.3 x 10-"' M to 4.5 x 10-"1 M ATRA in the culture medium, calculated from ATRA levels present in human plasma, i.e. 4-14 nM. To date, only indirect evidence suggested that retinoids could be removed from the serum by DCC treatment (Mummery et al, 1991) . Retinol, a possible source of RA, was harder to extract and about 40% could not be removed. We assumed that the remaining amount of retinol did not interfere with our results as MCF-7 cells are unable to convert retinol into ATRA (Krekels et al, 1997) .
The antineoplastic activity of synthetic retinoids, such as for example N-(4-hydroxyphenyl)retinamide, has been amply described. In contrast, limited and conflicting results have been reported about the activity of naturally occurring ATRA metabolites in tumour cells. The catabolite 4-oxo-ATRA has been shown to bind to RARs (Pijnappel et al, 1993) . Furthermore, both 4-oxo-ATRA and 5,6-epoxy-ATRA can activate RAR-dependent gene transcription in co-transfected CV-1 cells (Duell et al, 1992) . However, their activity in our study was higher than would have been expected from previous reports where these catabolites were found to be less potent than ATRA in (a) the inhibition of growth and the inhibition of hormone isobutylmethylxanthine-inducible tyrosinase activity of Cloudman S-91 mouse melanoma cells (Lotan et al, 1980; Reynolds et al, 1993) ; (b) the induction of differentiation of F9 mouse teratocarcinoma cells as measured by ELISA for laminin (Williams et al, 1987) ; and (c) the induction of differentiation and inhibition of proliferation of BA-HAN-IC rat rhabdomyosarcoma cells (Ramp et al, 1994) . In contrast, both catabolites have been reported to be virtually inactive (Frolik et al, 1979; Silva et al, 1987) . In our MCF-7 model system, the catabolites 4-oxo-ATRA and 5,6-epoxy-ATRA were as potent as ATRA at concentrations of 10-8 M and 10-7 M, but were twofold less potent at 10-6 M. It is clear that a complex phenomenon is occurring for which there is no obvious explanation. It is very unlikely that the observed antiproliferative activity of 4-oxo-ATRA and 5,6-epoxy-ATRA was due to conversion back to ATRA as the reactions involved in their formation are irreversible (Roberts et al, 1980; Napoli et al, 1982) . Although conversion to other active retinoids is conceivable, such compounds have yet to be identified (Reynolds et al, 1993) . To date, only in non-tumour models, namely in a model of positional specification (Pijnappel et al, 1993) and in spermatogonia (Gaemers et al, 1996) , has 4-oxo-ATRA been shown to be as potent as ATRA.
ATRA catabolism, under the present culture conditions, was induced to the same extent, as described previously (Wouters et al, 1992; Krekels et al, 1997) . Only the supematant was analysed for the presence of ATRA metabolites. We have previously shown that in the cell extract the same overall metabolite profile can be found (Wouters et al, 1992) . Using HPLC analysis peaks were identified that co-eluted with authentic 4-hydroxy-ATRA and 4-oxo ATRA. No 5,6-epoxy-ATRA could be detected under basal culture conditions nor after the induction of ATRA catabolism, indicating that 5,6-epoxy-ATRA was either not formed in vitro or formed in quantities below the detection limit. Therefore, it is unlikely that 5,6-epoxidation is a major catabolic pathway of ATRA in MCF-7 cells. In addition, other polar metabolites could be detected but their nature remains to be elucidated. We cannot exclude the possibility that these metabolites possess antiproliferative activity. In this context it is interesting to remark, however, that we have shown previously that the antiproliferative activity of ATRA can be enhanced by the addition of an inhibitor of ATRA catabolism (Wouters et al, 1992; Van heusden et al, 1996) , suggesting that catabolism of ATRA is not necessary to inhibit MCF-7 cell proliferation. The exact nature of the apolar peak, which has been described previously (Wouters et al, 1992) , also remains to be determined.
Recently, Takatsuka et al (1996) showed a positive relationship between ATRA-induced growth inhibition of human breast cancer cells and intracellular ATRA metabolism, suggesting that a metabolite of ATRA, rather than the parent compound itself, could be responsible for the observed growth inhibition. It is important to note, however, that these experiments were conducted under serum-free conditions, resulting in an altered bioavailability of ATRA to cells (Hodam and Creek, 1996) . Our data showed that 4-oxo-ATRA and 5,6-epoxy-ATRA are strong inhibitors of MCF-7 cell proliferation. However, as 5,6-epoxy-ATRA could not be identified in our cell culture system and 4-oxo-ATRA was formed to only a limited extent, our results do not favour the hypothesis that these catabolites are responsible for the observed growth inhibition when given ATRA.
The ability of ATRA to isomerize in cell culture (Urbach and Rando, 1994) further complicates the interpretation of its antiproliferative activity. In the present study, isomerization of ATRA to 9-cis-RA and 13-cis-RA was also observed, but only to a limited extent. This process was not enzymatic as it also occurred in the absence of cells, in agreement with previous results (Urbach and Rando, 1994) . The major isomer detected was the all-trans form of RA. The naturally occurring stereoisomer 9-cis-RA acts as a pan agonist that can bind and activate both RARs and RXRs (Chambon, 1996) . 9-cis-RA was equipotent to ATRA in inhibiting MCF-7 cell proliferation at all concentrations tested, in agreement with previous reports (Rubin et al, 1994) . The ability of the naturally occurring stereoisomer 13-cis-RA to bind and transactivate RARs is controversial. The antiproliferative activity of 1 3-cis-RA has been described to be less (Redfern et al, 1990) or equal (Frey et al, 1991) to that of ATRA. In our experiments, 13-cis-RA, at concentrations of 10-8 M and 1 07 M, was equipotent to ATRA in inhibiting the growth of MCF-7 cells, in agreement with previous reports (Frey et al, 1991) and with its therapeutic effect in some forms of cancer.
In conclusion, we can state that the naturally occurring catabolites and isomers of ATRA show significant antiproliferative activity in MCF-7 human breast cancer cells. However, as these catabolites and isomers were formed from ATRA to only a limited extent, our findings suggest that they cannot be responsible for the observed growth inhibition induced by ATRA.
